ArticleThe EMBO journal1995
Thrombopoietin activates a STAT5-like factor in hematopoietic cells.
Article in The EMBO journal, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 216 citations in OpenAlex.
- Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.Cancers · 2025Review
- Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition.Blood advances · 2025Article
- Transcriptional Regulation of Emergency Granulopoiesis in Leukemia.Frontiers in immunology · 2018Review
- Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases.Journal of hematology & oncology · 2013Review
- Review
- Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.PloS one · 2013Article
- Review
- Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes.European journal of immunology · 2010Article
- Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.The international journal of biochemistry & cell biology · 2010Review
- Thrombopoietin in normal and neoplastic stem cell development.Best practice & research. Clinical haematology · 2009Review
- Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.Molecular and cellular biology · 2008Article
- New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation.Seminars in cell & developmental biology · 2008Review
- Signal transducer and activator of transcription 5A/B in prostate and breast cancers.Endocrine-related cancer · 2008Review
- Article
- Interleukin 2 plays a central role in Th2 differentiation.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression.Molecular and cellular biology · 2003Article
- Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo).Oncogene · 2001Article
- The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors.Molecular and cellular biology · 2000Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombopoietin (TPO) is a newly cloned cytokine which is the major regulator of circulating platelet levels, acting on both proliferation and differentiation of megakaryocytes. We have investigated the ability of TPO to activate the JAK/STAT pathway in megakaryocytic cell lines. We used either the granulocyte-macrophage colony-stimulating factor (GM-CSF)- and/or erythropoietin (EPO)-dependent UT7 cell line in which the murine TPO receptor (mumpl) had been transfected (mumpl-UT7 transfectants) or the MO7E and DAMI cells which express endogenous human TPO receptors. We demonstrated that TPO activates the kinase JAK2 and a STAT5-like transcriptional factor but not STAT1, STAT2, STAT3 or STAT4, in a very rapid and transient manner. In order to better ascertain the specificity of the activation of STAT5-related factor by TPO, we investigated the effect of other cytokines/growth factors. Both GM-CSF and EPO activated the STAT5-like factor. In contrast, neither interferon (IFN)-gamma nor the mitogenic stem cell factor (SCF) activated STAT5, although IFN-gamma did activate STAT1 in those cells. The hematopoietic DNA binding activity related to STAT5 was identified as a p97 tyrosine-phosphorylated protein band which exhibited identical gel mobility to the mammary STAT5. Because v-mpl, a truncated form of the TPO receptor c-mpl, was shown to be oncogenic, we tested the activity of v-mpl on STAT5 and found STAT5 constitutively activated in two different v-mpl-expressing cells, the transiently transfected Cos7 cells and the stable v-mpl-UT7 transfectants. Overall, our data indicate that STAT5 is widely expressed in hematopoietic cells and activated by a number of cytokines, including TPO, GM-CSF and EPO, but not by IFN-gamma or SCF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.